<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04761601</url>
  </required_header>
  <id_info>
    <org_study_id>UCT01097-001</org_study_id>
    <nct_id>NCT04761601</nct_id>
  </id_info>
  <brief_title>First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1, First in Human, Dose-Escalation Study of UCT-01-097 in Participants With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>1200 Pharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>1200 Pharma, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and&#xD;
      antitumor activity of UCT-01-097 in patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 23, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events and serious adverse events</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE Version 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>28 Days</time_frame>
    <description>Highest administered dose with &lt; 33% participants experiencing dose limiting toxicity (DLT) in the first 6 DLT evaluable participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Based on the maximum tolerated dose, cumulative safety, and pharmacokinetic data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma UCT-01-097 Concentration (Cmax)</measure>
    <time_frame>Day 1</time_frame>
    <description>PK assessment for UCT-01-097</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma UCT-01-097 Concentration at steady state (Cmax,ss)</measure>
    <time_frame>Day 15</time_frame>
    <description>PK assessment for UCT-01-097</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UCT-01-097 Trough Plasma Concentration (Cmin)</measure>
    <time_frame>Day 1</time_frame>
    <description>PK assessment for UCT-01-097</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UCT-01-097 Trough Plasma Concentration at Steady State (Cmin,ss)</measure>
    <time_frame>Day 15</time_frame>
    <description>PK assessment for UCT-01-097</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Plasma UCT-01-097 Concentration (Tmax)</measure>
    <time_frame>Cycle 1 (each cycle is 28 days)</time_frame>
    <description>PK assessment for UCT-01-097</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve Over Dosing Interval (AUCtau) of UCT-01-097</measure>
    <time_frame>Day 15</time_frame>
    <description>PK assessment for UCT-01-097</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) of UCT-01-097</measure>
    <time_frame>Cycle 1 (each cycle is 28 days)</time_frame>
    <description>PK assessment for UCT-01-097</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of UCT-01-097</measure>
    <time_frame>Cycle 1 (each cycle is 28 days)</time_frame>
    <description>PK assessment for UCT-01-097</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio (Rac) of UCT-01-097</measure>
    <time_frame>Cycle 1 (each cycle is 28 days)</time_frame>
    <description>PK assessment for UCT-01-097</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (t1/2) of UCT-01-097</measure>
    <time_frame>Cycle 1 (each cycle is 28 days)</time_frame>
    <description>PK assessment for UCT-01-097</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Percentage of participants with best response of CR or PR according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Time from start of treatment to complete response or partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Time from complete response or partial response to objective disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>PFS is defined as the time from the start of the treatment until objective disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 Year Overall Survival (1YOS)</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of participants alive at 1 year from the start of treatment to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Year Overall Survival (2YOS)</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of participants alive at 2 years from the start of treatment to death from any cause</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Dose Finding as Monotherapy - Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion as Monotherapy - Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Finding in Combination - Part 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UCT-01-097</intervention_name>
    <description>Orally available kinase inhibitor</description>
    <arm_group_label>Dose Finding as Monotherapy - Part 1</arm_group_label>
    <arm_group_label>Dose Finding in Combination - Part 3</arm_group_label>
    <arm_group_label>Expansion as Monotherapy - Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine injection for intravenous use.</description>
    <arm_group_label>Dose Finding in Combination - Part 3</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel protein-bound particles for injectable suspension (albumin-bound).</description>
    <arm_group_label>Dose Finding in Combination - Part 3</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced solid tumor&#xD;
&#xD;
          -  Measurable disease, per RECIST v1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has not recovered [recovery is defined as NCI CTCAE, version 5.0, grade â‰¤1] from the&#xD;
             acute toxicities of previous therapy, except treatment-related alopecia or laboratory&#xD;
             abnormalities otherwise meeting eligibility requirements&#xD;
&#xD;
          -  Received prior chemotherapeutic, investigational, or other therapies for the treatment&#xD;
             of cancer within 14 days with small molecule and within 28 days with biologic before&#xD;
             the first dose of UCT-01-097&#xD;
&#xD;
          -  Progressive or symptomatic brain metastases&#xD;
&#xD;
          -  Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active,&#xD;
             uncontrolled infection&#xD;
&#xD;
          -  History of phosphate or calcium disorder&#xD;
&#xD;
          -  History of significant cardiac disease&#xD;
&#xD;
          -  History or current evidence/risk of retinopathy&#xD;
&#xD;
          -  History of myelodysplastic syndrome (MDS) or AML&#xD;
&#xD;
          -  History of another cancer within 3 years before Day 1 of study treatment, with the&#xD;
             exception of basal or squamous cell carcinoma of the skin that has been definitively&#xD;
             treated. A history of other malignancies with a low risk of recurrence, including&#xD;
             appropriately treated ductal carcinoma in situ (DCIS) of the breast and prostate&#xD;
             cancer with a Gleason score less than or equal to 6, are also not excluded&#xD;
&#xD;
          -  If female, is pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Letrent, PharmD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>1200 Pharma, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen Letrent, PharmD, PhD</last_name>
    <phone>858-342-6652</phone>
    <email>stephen.letrent@1200pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA - JCCC Clinical Research Unit</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zev Wainberg, MD</last_name>
      <phone>310-586-2094</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

